Geode Capital Management: Emergent Biosolutions EBS Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 8.39 M | Venta |
1,271,161
-66,082
| -5% | -USD 434 k | ﹤0.01% | 2579 |
|
|
2026
Q2 | USD 11.2 M | Compra |
1,337,243
+64,334
| +5% | +USD 538 k | ﹤0.01% | 2475 |
|
|
2026
Q1 | USD 10.6 M | Compra |
1,272,909
+22,899
| +2% | +USD 237 k | ﹤0.01% | 2349 |
|
|
2025
Q4 | USD 15.5 M | Venta |
1,250,010
-28,683
| -2% | -USD 307 k | ﹤0.01% | 2147 |
|
|
2025
Q3 | USD 11.3 M | Venta |
1,278,693
-305
| -0% | -USD 2.37 k | ﹤0.01% | 2352 |
|
|
2025
Q2 | USD 8.16 M | Compra |
1,278,998
+666,708
| +109% | +USD 3.82 M | ﹤0.01% | 2483 |
|
|
2025
Q1 | USD 2.98 M | Compra |
612,290
+21,428
| +4% | +USD 177 k | ﹤0.01% | 2889 |
|
|
2024
Q4 | USD 5.65 M | Compra |
590,862
+8,904
| +2% | +USD 81.7 k | ﹤0.01% | 2681 |
|
|
2024
Q3 | USD 4.86 M | Compra |
581,958
+25,776
| +5% | +USD 234 k | ﹤0.01% | 2771 |
|
|
2024
Q2 | USD 3.79 M | Venta |
556,182
-565,013
| -50% | -USD 2.43 M | ﹤0.01% | 2874 |
|
|
2024
Q1 | USD 2.84 M | Compra |
1,121,195
+23,976
| +2% | +USD 54 k | ﹤0.01% | 2973 |
|
|
2023
Q4 | USD 2.63 M | Compra |
1,097,219
+78,184
| +8% | +USD 184 k | ﹤0.01% | 3005 |
|
|
2023
Q3 | USD 3.47 M | Compra |
1,019,035
+94,551
| +10% | +USD 524 k | ﹤0.01% | 2822 |
|
|
2023
Q2 | USD 6.79 M | Compra |
924,484
+28,030
| +3% | +USD 260 k | ﹤0.01% | 2529 |
|
|
2023
Q1 | USD 9.29 M | Compra |
896,454
+38,040
| +4% | +USD 460 k | ﹤0.01% | 2295 |
|
|
2022
Q4 | USD 10.1 M | Compra |
858,414
+21,994
| +3% | +USD 340 k | ﹤0.01% | 2258 |
|
|
2022
Q3 | USD 17.6 M | Compra |
836,420
+4,469
| +0.5% | +USD 124 k | ﹤0.01% | 1833 |
|
|
2022
Q2 | USD 25.8 M | Compra |
831,951
+14,304
| +2% | +USD 488 k | ﹤0.01% | 1571 |
|
|
2022
Q1 | USD 33.6 M | Venta |
817,647
-25,151
| -3% | -USD 1.11 M | ﹤0.01% | 1535 |
|
|
2021
Q4 | USD 36.6 M | Compra |
842,798
+19,726
| +2% | +USD 892 k | ﹤0.01% | 1538 |
|
|
2021
Q3 | USD 41.2 M | Venta |
823,072
-19,805
| -2% | -USD 1.2 M | 0.01% | 1432 |
|
|
2021
Q2 | USD 53.1 M | Compra |
842,877
+18,945
| +2% | +USD 1.22 M | 0.01% | 1254 |
|
|
2021
Q1 | USD 76.6 M | Compra |
823,932
+134,198
| +19% | +USD 13.7 M | 0.01% | 919 |
|
|
2020
Q4 | USD 61.8 M | Compra |
689,734
+39,673
| +6% | +USD 3.64 M | 0.01% | 965 |
|
|
2020
Q3 | USD 67.2 M | Venta |
650,061
-4,604
| -0.7% | -USD 496 k | 0.01% | 770 |
|
|
2020
Q2 | USD 51.8 M | Compra |
654,665
+13,373
| +2% | +USD 997 k | 0.01% | 877 |
|
|
2020
Q1 | USD 37.1 M | Compra |
641,292
+39,965
| +7% | +USD 2.3 M | 0.01% | 923 |
|
|
2019
Q4 | USD 32.4 M | Compra |
601,327
+23,197
| +4% | +USD 1.26 M | 0.01% | 1230 |
|
|
2019
Q3 | USD 30.2 M | Venta |
578,130
-14,243
| -2% | -USD 664 k | 0.01% | 1200 |
|
|
2019
Q2 | USD 28.6 M | Compra |
592,373
+48,789
| +9% | +USD 2.34 M | 0.01% | 1233 |
|
|
2019
Q1 | USD 27.5 M | Compra |
543,584
+21,768
| +4% | +USD 1.28 M | 0.01% | 1204 |
|
|
2018
Q4 | USD 30.9 M | Compra |
521,816
+53,986
| +12% | +USD 3.48 M | 0.01% | 991 |
|
|
2018
Q3 | USD 30.8 M | Compra |
467,830
+74,971
| +19% | +USD 4.37 M | 0.01% | 1106 |
|
|
2018
Q2 | USD 19.8 M | Compra |
392,859
+56,978
| +17% | +USD 2.97 M | 0.01% | 1362 |
|
|
2018
Q1 | USD 17.7 M | Compra |
335,881
+3,954
| +1% | +USD 197 k | 0.01% | 1349 |
|
|
2017
Q4 | USD 15.4 M | Compra |
331,927
+2,536
| +0.8% | +USD 107 k | 0.01% | 1454 |
|
|
2017
Q3 | USD 13.3 M | Compra |
329,391
+13,932
| +4% | +USD 504 k | ﹤0.01% | 1522 |
|
|
2017
Q2 | USD 10.7 M | Compra |
315,459
+1,261
| +0.4% | +USD 38.9 k | ﹤0.01% | 1618 |
|
|
2017
Q1 | USD 9.12 M | Compra |
314,198
+25,953
| +9% | +USD 790 k | ﹤0.01% | 1677 |
|
|
2016
Q4 | USD 9.46 M | Compra |
288,245
+13,426
| +5% | +USD 403 k | ﹤0.01% | 1622 |
|
|
2016
Q3 | USD 8.66 M | Compra |
274,819
+26,428
| +11% | +USD 768 k | ﹤0.01% | 1586 |
|
|
2016
Q2 | USD 6.98 M | Compra |
248,391
+31,374
| +14% | +USD 1.23 M | ﹤0.01% | 1678 |
|
|
2016
Q1 | USD 7.89 M | Compra |
217,017
+4,680
| +2% | +USD 165 k | ﹤0.01% | 1552 |
|
|
2015
Q4 | USD 8.5 M | Venta |
212,337
-9,432
| -4% | -USD 329 k | ﹤0.01% | 1492 |
|
|
2015
Q3 | USD 6.32 M | Compra |
221,769
+13,275
| +6% | +USD 437 k | ﹤0.01% | 1683 |
|
|
2015
Q2 | USD 6.87 M | Compra |
208,494
+13,982
| +7% | +USD 433 k | ﹤0.01% | 1690 |
|
|
2015
Q1 | USD 5.59 M | Compra |
194,512
+9,056
| +5% | +USD 260 k | ﹤0.01% | 1797 |
|
|
2014
Q4 | USD 5.05 M | Compra |
185,456
+570
| +0.3% | +USD 13.6 k | ﹤0.01% | 1811 |
|
|
2014
Q3 | USD 3.94 M | Compra |
184,886
+18,685
| +11% | +USD 428 k | ﹤0.01% | 1913 |
|
|
2014
Q2 | USD 3.73 M | Venta |
166,201
-25,852
| -13% | -USD 602 k | ﹤0.01% | 1969 |
|
|
2014
Q1 | USD 4.85 M | Compra |
192,053
+34,786
| +22% | +USD 879 k | ﹤0.01% | 1793 |
|
|
2013
Q4 | USD 3.62 M | Compra |
157,267
+11,565
| +8% | +USD 241 k | ﹤0.01% | 1937 |
|
|
2013
Q3 | USD 2.78 M | Compra |
145,702
+5,864
| +4% | +USD 105 k | ﹤0.01% | 1974 |
|
|
2013
Q2 | USD 2.02 M | Compra |
+139,838
| Nuevas | +USD 2.02 M | ﹤0.01% | 2028 |
|
Otros fondos que tienen EBS en su portafolio
Posición de Geode Capital Management en EBS: resumen de T3 2026
Geode Capital Management redujo su participación en Emergent Biosolutions (EBS) en 4.9% durante T3 2026, al vender acciones por un valor estimado de USD 434 k y quedarse con 1,271,161 acciones valuadas en USD 8.39 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #2579.
Geode Capital Management reportó por primera vez una posición en EBS en T2 2013 y desde entonces la ha mantenido en 54 trimestres. La posición alcanzó su máximo de USD 76.6 M en T1 2021. Al cierre de T3 2026, 186 fondos que sigue Wall St. Rank mantienen una posición en EBS.
- Al cierre de T3 2026, Geode Capital Management tenía 1,271,161 acciones de Emergent Biosolutions con un valor de USD 8.39 M.
- Geode Capital Management vendió 66,082 acciones de Emergent Biosolutions en T3 2026, por un valor estimado de USD 434 k.
- Emergent Biosolutions representó el ﹤0.01% del portafolio de Geode Capital Management en T3 2026 y fue su posición número 2579.
- Geode Capital Management reportó por primera vez una posición en Emergent Biosolutions en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- La posición de Geode Capital Management en Emergent Biosolutions alcanzó su máximo de USD 76.6 M en T1 2021.
- Al cierre de T3 2026, 186 fondos que sigue Wall St. Rank tenían Emergent Biosolutions en su portafolio.
Según el informe 13F de Geode Capital Management correspondiente a T3 2026, presentado el 6 nov 2026.